Shares of Perrigo (NYSE:PRGO) have been given a consensus recommendation of “Hold” by the nineteen analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $93.44.
PRGO has been the topic of several research reports. Canaccord Genuity set a $105.00 price target on shares of Perrigo and gave the company a “buy” rating in a report on Monday, March 26th. Cantor Fitzgerald set a $107.00 target price on shares of Perrigo and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Oppenheimer reiterated a “buy” rating and set a $98.00 target price on shares of Perrigo in a research report on Tuesday, February 27th.
In other Perrigo news, CEO Uwe Roehrhoff acquired 7,500 shares of the company’s stock in a transaction on Monday, March 5th. The shares were acquired at an average cost of $81.85 per share, with a total value of $613,875.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,900 shares in the company, valued at $401,065. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is owned by corporate insiders.
Shares of Perrigo stock traded down $2.67 during midday trading on Wednesday, hitting $77.82. 1,544,358 shares of the company traded hands, compared to its average volume of 1,018,696. The firm has a market capitalization of $11,535.68, a PE ratio of 15.78, a price-to-earnings-growth ratio of 2.03 and a beta of 0.76. The company has a current ratio of 1.96, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Perrigo has a 12 month low of $63.68 and a 12 month high of $95.93.
Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Thursday, March 1st. The company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.03. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.26 billion. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The firm’s revenue was down 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.24 EPS. research analysts anticipate that Perrigo will post 5.23 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://weekherald.com/2018/04/26/perrigo-prgo-receives-91-88-average-target-price-from-analysts.html.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.